Veradermics MANE Cash Flow Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|
| —— | —— | —— | -$32.27M-21.8% | ||
| —— | —— | —— | $400.5K+60.2% | ||
| —— | —— | —— | -$201.5K-131% | ||
| —— | —— | —— | $91.25K-92.8% | ||
| —— | —— | —— | $888.75K-25.0% | ||
| —— | —— | —— | -$7K— | ||
| -$43K+75.5% | -$175.5K+43.0% | -$308K+30.1% | -$440.5K+23.1% | ||
| —— | —— | —— | -$31.08M-31.2% | ||
| —— | —— | —— | $19K— | ||
| —— | —— | —— | $15.73M— | ||
| $25.02M+33.3% | $18.76M+50.0% | $12.51M+100% | $6.25M— | ||
| —— | —— | —— | -$15.75M— | ||
| $0-100% | $211.25K-50.0% | $422.5K-33.3% | $633.75K-25.0% | ||
| —— | —— | —— | $0— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | $53.78M-11.1% | ||
| —— | —— | —— | $6.95M-81.1% | ||
| $0-100% | $23.75K-50.0% | $47.5K-33.3% | $71.25K-25.0% | ||
| $0— | $0— | $0— | $0— | ||
| —— | —— | —— | $13K— | ||
| $647K+33.3% | $485.25K+50.0% | $323.5K+100% | $161.75K— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | $809.75K-31.7% | ||
| —— | —— | —— | -$431.75K+24.7% | ||
| $0-100% | $58.5K-50.0% | $117K-33.3% | $175.5K-25.0% | ||
| —— | —— | —— | $1.12M+10.3% | ||
| —— | —— | —— | $0— | ||
| $447K+10.1% | $406K+11.2% | $365K+12.7% | $324K+14.5% | ||
| —— | —— | —— | —— | ||
| $0-100% | $211.25K-50.0% | $422.5K-33.3% | $633.75K-25.0% | ||
| $0-100% | $233K-50.0% | $466K-33.3% | $699K-25.0% | ||
| $0-100% | $2.61M-50.0% | $5.22M-33.3% | $7.83M-25.0% | ||
| —— | —— | —— | $0— | ||
| $0-100% | $62.5K-50.0% | $125K-33.3% | $187.5K-25.0% | ||
| $0-100% | $291.5K-50.0% | $583K-33.3% | $874.5K-25.0% | ||
| $0-100% | $2.13M-50.0% | $4.25M-33.3% | $6.38M-25.0% | ||
| —— | —— | —— | $90K— | ||
| —— | —— | —— | —— | ||
| $0-100% | $758.25K-50.0% | $1.52M-33.3% | $2.27M-25.0% | ||
| $0— | $0— | $0— | $0— | ||
| —— | —— | —— | -$31.1M-31.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Veradermics generate?
- Veradermics (MANE) generated -$46.3M in operating cash flow over the trailing twelve months.
- What is Veradermics 's free cash flow?
- After $19.0K of capital expenditures, Veradermics 's free cash flow was -$46.3M over the trailing twelve months.
- Where does Veradermics 's cash flow data come from?
- Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.